Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial-Reference-Cited by-同舟云学术

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

Published:2016-06 Issue:6 Volume:27 Page:1047-1054
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Harbeck N.,Iyer S.,Turner N.,Cristofanilli M.,Ro J.,André F.,Loi S.,Verma S.,Iwata H.,Bhattacharyya H.,Puyana Theall K.,Bartlett C.H.,Loibl S.

Funder

Pfizer Inc.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/6/1047/19446632/mdw139.pdf

Reference14 articles.

1. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6;Toogood;J Med Chem,2005

2. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro;Finn;Breast Cancer Res,2009

3. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study;Finn;Lancet Oncol,2015

4. Palbociclib in hormone-receptor-positive advanced breast cancer;Turner;N Engl J Med,2015

5. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer;Butters;Cochrane Database Syst Rev,2010

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial;The Lancet Oncology;2024-09

2. Palbociclib: Randomized Studies and Real-world Evidence as the Basis for Therapeutic Planning in Metastatic Breast Cancer;Geburtshilfe und Frauenheilkunde;2024-09

3. The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?;Cancers;2024-05-11

4. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors;European Journal of Pharmacology;2024-05

5. Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer;Journal of Pharmacy Practice;2024-04-23